5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
A guide to bremelanotide (Vyleesi) use in patients 65 and older, covering pharmacokinetics, safety signals, dose adjustments, cardiovascular precautions, and transition-of-care planning for geriatric patients with hypoactive sexual desire disorder.
A deep dive into the geriatric use of bremelanotide (Vyleesi), pharmacokinetics, safety signals, clinical trial data, and prescribing guidance for adults 65 and older.
Bremelanotide (Vyleesi) is FDA-approved only for premenopausal adults. This clinical guide explains why it has no established role in pediatric patients under 12, what parents and clinicians should know about safety, and how to approach school and activity planning when a household member uses it.
A guide for caregivers administering bremelanotide (Vyleesi) to adolescents aged 12 to 17, covering injection technique, timing, safety monitoring, and FDA-approved use parameters.
A complete clinical guide to administering bremelanotide (Vyleesi) in patients aged 65 and older, covering pharmacokinetics, dose timing, caregiver injection technique, contraindications, and monitoring protocols prepared by the HealthRX.com Editorial Team.